Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 19 GBX -1.3% Market Closed
Market Cap: 78.3m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Creo Medical Group PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Creo Medical Group PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Creo Medical Group PLC
LSE:CREO
Income from Continuing Operations
-ÂŁ22.4m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Income from Continuing Operations
$305m
CAGR 3-Years
-18%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Income from Continuing Operations
$23.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
EKF Diagnostics Holdings PLC
LSE:EKF
Income from Continuing Operations
ÂŁ5.1m
CAGR 3-Years
-32%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Angle PLC
LSE:AGL
Income from Continuing Operations
-ÂŁ18m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Income from Continuing Operations
-$18.5m
CAGR 3-Years
-111%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
78.3m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.92 GBX
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Creo Medical Group PLC's Income from Continuing Operations?
Income from Continuing Operations
-22.4m GBP

Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's Income from Continuing Operations amounts to -22.4m GBP.

What is Creo Medical Group PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-9%

Over the last year, the Income from Continuing Operations growth was 11%. The average annual Income from Continuing Operations growth rates for Creo Medical Group PLC have been -2% over the past three years , -9% over the past five years .

Back to Top